MX2019010573A - Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno. - Google Patents
Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno.Info
- Publication number
- MX2019010573A MX2019010573A MX2019010573A MX2019010573A MX2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A
- Authority
- MX
- Mexico
- Prior art keywords
- montelukast
- receptor antagonists
- leukotriene receptor
- treatment
- improved bioavailability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762478876P | 2017-03-30 | 2017-03-30 | |
PCT/CA2018/050389 WO2018176149A1 (en) | 2017-03-30 | 2018-03-29 | Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019010573A true MX2019010573A (es) | 2019-10-24 |
Family
ID=63673863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019010573A MX2019010573A (es) | 2017-03-30 | 2018-03-29 | Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3600265A1 (de) |
JP (1) | JP2020512309A (de) |
KR (1) | KR20190128637A (de) |
CN (1) | CN110381931A (de) |
AU (1) | AU2018241534A1 (de) |
BR (1) | BR112019018388A2 (de) |
CA (1) | CA3056944A1 (de) |
MX (1) | MX2019010573A (de) |
WO (1) | WO2018176149A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3150213A1 (en) * | 2018-09-14 | 2022-03-19 | Intelgenx Corp. | TREATMENT METHOD AND DEVICE FOR ENHANCED BIOAVAILABILITY OF MONTELUKAST, A LEUCOTRIEN RECEPTOR ANTAGONIST |
US20210393611A1 (en) * | 2018-11-05 | 2021-12-23 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
US11602504B2 (en) * | 2018-11-05 | 2023-03-14 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
CN110496124A (zh) * | 2019-04-10 | 2019-11-26 | 中山大学附属第五医院 | 治疗脉管畸形的化合物 |
CN114931578A (zh) * | 2022-05-16 | 2022-08-23 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 孟鲁司特在制备用于治疗***性红斑狼疮药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101074271B1 (ko) * | 2009-06-25 | 2011-10-17 | (주)차바이오앤디오스텍 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
KR101077468B1 (ko) * | 2011-03-04 | 2011-11-07 | (주)차바이오앤디오스텍 | 안정한 경구용 속용 필름 제제 |
EA038558B1 (ru) * | 2013-10-14 | 2021-09-14 | Зим Лэбораториз Лимитед | Водорастворимая фармацевтическая пленка с повышенной стабильностью |
US9668970B2 (en) * | 2013-12-02 | 2017-06-06 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
CN104784157B (zh) * | 2015-04-04 | 2018-06-26 | 齐鲁制药有限公司 | 一种稳定的孟鲁司特口腔薄膜剂 |
-
2018
- 2018-03-29 JP JP2019548270A patent/JP2020512309A/ja active Pending
- 2018-03-29 AU AU2018241534A patent/AU2018241534A1/en not_active Abandoned
- 2018-03-29 BR BR112019018388A patent/BR112019018388A2/pt not_active Application Discontinuation
- 2018-03-29 MX MX2019010573A patent/MX2019010573A/es unknown
- 2018-03-29 EP EP18774366.1A patent/EP3600265A1/de not_active Withdrawn
- 2018-03-29 KR KR1020197025967A patent/KR20190128637A/ko unknown
- 2018-03-29 WO PCT/CA2018/050389 patent/WO2018176149A1/en unknown
- 2018-03-29 CA CA3056944A patent/CA3056944A1/en active Pending
- 2018-03-29 CN CN201880016281.6A patent/CN110381931A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020512309A (ja) | 2020-04-23 |
AU2018241534A1 (en) | 2019-09-26 |
CA3056944A1 (en) | 2018-10-04 |
KR20190128637A (ko) | 2019-11-18 |
EP3600265A1 (de) | 2020-02-05 |
CN110381931A (zh) | 2019-10-25 |
BR112019018388A2 (pt) | 2020-04-07 |
WO2018176149A1 (en) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019010573A (es) | Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno. | |
MX2019004096A (es) | Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion. | |
PH12015501531A1 (en) | Crenolanib for treating flt3 mutated proliferative disorders | |
MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
WO2015123576A3 (en) | Targeted nanoparticle compositions and methods of their use to treat obesity | |
MY193694A (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
HRP20211046T1 (hr) | Upotreba derivata benzimidazola kod noćnog proboja kiseline | |
MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
MX2016009231A (es) | Administracion de tasimelteon en condiciones de ayuno. | |
MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
SI2413933T1 (en) | 2,4,6-TRIUFLORO-N- (6- (1-METHYL-PIPERIDIN-4-CARBONYL) -PYRIDIN-2-YL)-BENZAMIDE FOR THRESHOLD OF MIGRINE OVER ORAL OR INTRAVEN | |
TR201819662T4 (tr) | Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi. | |
PH12016500063A1 (en) | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation | |
CA3150213A1 (en) | TREATMENT METHOD AND DEVICE FOR ENHANCED BIOAVAILABILITY OF MONTELUKAST, A LEUCOTRIEN RECEPTOR ANTAGONIST | |
WO2015011653A9 (en) | pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM | |
EA201890575A1 (ru) | Композиции и способы сенсибилизации паразитов к лекарственным средствам | |
PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
WO2016193456A3 (en) | Opioid receptor antagonist for use in treating patients with severe constipation | |
CY1120693T1 (el) | Συνδυασμος ενος αναστολεα κινασης ρι3 με πακλιταξελη για χρηση στη θεραπεια ή προληψη ενος καρκινου κεφαλης και τραχηλου | |
EA201491046A1 (ru) | Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли | |
BR0313423A (pt) | Medicamento para o tratamento contra a ânsia por uma substância devido a uma dependência | |
WO2018231176A3 (en) | COMBINATIONS OF DICLOFENAC AND H2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN AND INFLAMMATION | |
EA201991384A1 (ru) | Комбинации диклофенака и антагонистов h2-рецептора для лечения боли и воспаления |